Araştırma Makalesi

Examination of Cases Who Had Molecular Testing with the Presumptive Diagnosis of Cystic Fibrosis: Experience of a Single Center

Cilt: 10 Sayı: 3 15 Eylül 2025
PDF İndir
EN TR

Examination of Cases Who Had Molecular Testing with the Presumptive Diagnosis of Cystic Fibrosis: Experience of a Single Center

Abstract

Objective: Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene, leading to multisystem involvement. Early diagnosis is crucial for managing complications and improving patient prognosis. This study aimed to evaluate the clinical and demographic characteristics and molecular analysis results of patients who underwent CFTR gene mutation analysis with a preliminary diagnosis of CF. Materials and Methods: A total of 34 patients were included in the study. Clinical and demographic data, along with genetic analysis results, were retrospectively examined. The frequency of symptoms associated with CF was determined, and the relationship between genetic findings and clinical manifestations was analyzed. Results: The most common reason for admission was respiratory symptoms, accounting for 64.7% of cases, followed by gastrointestinal complaints and malnutrition. Malnutrition was found to be significantly associated with a positive CFTR gene mutation (p=0.027). The risk of detecting a CFTR gene mutation was 5.667 times higher in patients with malnutrition. Conclusions: This study highlights the necessity of considering CF in the differential diagnosis of children presenting with recurrent respiratory tract infections and malnutrition, even in the absence of a positive family history. While respiratory symptoms were the most common reason for admission, malnutrition was found to be significantly more prevalent among mutation-positive cases. These findings underscore the importance of supporting careful clinical evaluation with genetic analysis in the diagnostic process of CF. Further large-scale, multicenter studies are needed to confirm and expand upon these results.

Keywords

Etik Beyan

İnsan deneklerin yer aldığı bu araştırma, ilgili tüm ulusal düzenlemelere ve kurumsal politikalara uygun olarak yürütülmüş ve Helsinki Bildirgesi ilkelerine uygun olarak gerçekleştirilmiştir. Çalışma, Düzce Üniversitesi Tıp Fakültesi Etik Kurulu tarafından onaylanmıştır (Tarih: 10.06.2024, karar no: 2024/126). Çalışmaya dahil edilmeden önce, tüm katılımcıların ebeveynlerine çalışmanın amacı, metodolojisi ve uygulaması hakkında bilgi verilmiş ve yazılı onamları alınmıştır.

Kaynakça

  1. Graeber SY, Mall MA. The future of cystic fibrosis treatment: From disease mechanisms to novel therapeutic approaches. Lancet. 2023;402(10408):1185-1198.
  2. Ong T, Ramsey BW. Cystic fibrosis: A review. JAMA. 2023;329(21):1859-1871.
  3. Chen Q, Shen Y, Zheng J. A review of cystic fibrosis: Basic and clinical aspects. Animal Model Exp Med. 2021;4(3):220-232.
  4. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020;109(5):893-899.
  5. Bierlaagh MC, Muilwijk D, Beekman JM, van der Ent CK. A new era for people with cystic fibrosis. Eur J Pediatr. 2021;180(9):2731-2739.
  6. Farrell PM. Why cystic fibrosis newborn screening programs have failed to meet original expectations… Thus far. Mol Genet Metab. 2023;40(1-2):107679. doi:10.1016/j.ymgme.2023.107679
  7. Weber SA, Ferrari GF. Incidence and evolution of nasal polyps in children and adolescents with cystic fibrosis. Braz J Otorhinolaryngol. 2008;74(1):16-20. 
  8. Yavas C, Dogan M, Ozgor B, Akbulut E, Eroz R. Novel biallelic nonsense mutation in IGHMBP2 gene linked to neuropathy (CMT2S): A comprehensive clinical, genetic and bioinformatic analysis of a Turkish patient with literature review. Brain Dev. 2025;47(1):104313. doi:10.1016/j.braindev.2024.104313

Ayrıntılar

Birincil Dil

İngilizce

Konular

Çocuk Sağlığı ve Hastalıkları (Diğer)

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

15 Eylül 2025

Gönderilme Tarihi

11 Şubat 2025

Kabul Tarihi

27 Haziran 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 10 Sayı: 3

Kaynak Göster

AMA
1.Kurt F, Eröz R. Examination of Cases Who Had Molecular Testing with the Presumptive Diagnosis of Cystic Fibrosis: Experience of a Single Center. OTSBD. 2025;10(3):218-224. doi:10.26453/otjhs.1637347

Creative Commons Lisansı
 

Online Türk Sağlık Bilimleri Dergisi Creative Commons Atıf-GayriTicari 4.0 Uluslararası Lisansı ile lisanslanmıştır.

Bu, Creative Commons Atıf Lisansı (CC BY-NC 4.0) şartları altında dağıtılan açık erişimli bir dergidir. Orijinal yazar(lar) veya lisans verenin adı ve bu dergideki orijinal yayının kabul görmüş akademik uygulamaya uygun olarak atıfta bulunulması koşuluyla, diğer forumlarda kullanılması, dağıtılması veya çoğaltılmasına izin verilir. Bu şartlara uymayan hiçbir kullanım, dağıtım veya çoğaltmaya izin verilmez.

Makale gönderme süreçleri ve "Telif Hakkı Devir Formu" hakkında yardım almak için tıklayınız.